172 results for "Heuser, Michael"
Showing 1–20 · 2.00 seconds · RSS
-
Journal Article Full text
Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Therapy-related myeloid neoplasms (t-MN) combine t-MDS and therapy related acute myeloid leukemia (t-AML) patients in one entity because of their similar pathogenesis, rapid progression from t-MDS to t-AML, and their equally poor prognosis. Treatment with epipodophyllotoxins like etoposide has been…
-
Journal Article Full text
Exploiting differential RNA splicing patterns: A potential new group of therapeutic targets in cancer
INTRODUCTION: Genetic characterization of cancer has uncovered the importance of differential or alternative RNA splicing for cancer development. Mutations in genes associated with splicing have been found in hematologic malignancies, but also in some solid cancers. Aberrant cancer specific RNA…
-
Journal Article Full text
Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
SIMPLE SUMMARY: Acute myeloid leukemia is a genetically heterogeneous disease and shows variable treatment outcomes. Genetic profiling has revealed different driver mutations in AML patients. Therefore, it is important to understand the biological impact of these mutations in leukemia…
-
Journal Article Full text
Resistance to targeted therapies in acute myeloid leukemia
The introduction of new targeted therapies to the treatment algorithm of acute myeloid leukemia (AML) offers new opportunities, but also presents new challenges. Patients diagnosed with AML receiving targeted therapies as part of lower intensity regimens will relapse inevitably due to primary or…
-
Journal Article Full text
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient
Acute myeloid leukemia (AML) is classified by risk groups according to a number of genetic mutations, which may occur alone or in combination with other mutations and chromosomal abnormalities. Prognosis and appropriate therapy can vary significantly based on a patient's genetic risk group, making…
-
Journal Article Full text
Treatment for Relapsed/Refractory Acute Myeloid Leukemia
Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis and treatment remains challenging. For the majority of r/r patients, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment approach. Salvage therapy is given in order to…
-
Journal Article Full text
Clonal Hematopoiesis of Indeterminate Potential
BACKGROUND: Patients with cytopenia are increasingly undergoing molecular genetic tests of periperal blood or bone marrow for diagnostic purposes. These tests can detect genetic mutations that do not have any morphological correlate in hematologic neoplasia such as myelodysplastic syndrome (MDS). A…
-
Journal Article Full text
Epigenetics in myelodysplastic syndromes
Epigenetic regulators are the largest group of genes mutated in MDS patients. Most mutated genes belong to one of three groups of genes with normal functions in DNA methylation, in H3K27 methylation/acetylation or in H3K4 methylation. Mutations in the majority of epigenetic regulators disrupt their…
-
Journal Article Full text
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
Patient- and leukemia-specific factors assessed at diagnosis classify patients with acute myeloid leukemia (AML) in risk categories that are prognostic for outcome. The induction phase with intensive chemotherapy in fit patients aims to reach a complete remission (CR) of less than 5% blasts in bone…
-
Journal Article Full text
Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and overall survival remains poor. Chemotherapy is the standard of care for intensive induction therapy. Patients who achieve a complete remission require post-remission therapies to prevent relapse. There is no standard of…
-
Journal Article Full text
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2
SIMPLE SUMMARY: The treatment of acute myeloid leukemia (AML) has improved in recent decennia by targeted therapy and allogeneic stem cell transplantation (allo-SCT). Hematological relapse in patients who have attained complete remission (CR) after chemotherapy remains a significant cause of…
-
Journal Article Full text
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
-
Journal Article Full text
Therapierefraktäre Anämie bei einem 35-jährigen Dialysepatienten nach Herztransplantation
This article presents a case of pure red cell aplasia in a 35-year-old heart transplant recipient on chronic hemodialysis. Elevated parvovirus B19 immunoglobulin M blood levels were detected along with a high viral load of 80 billion IU/ml quantified by polymerase chain reaction. Bone marrow…
-
Journal Article Full text
Teleradiotherapy Network: Applications and Feasibility for Providing Cost-Effective Comprehensive Radiotherapy Care in Low- and Middle-Income Group Countries for Cancer Patients
Globally, new cancer cases will rise by 57% within the next two decades, with the majority in the low- and middle-income countries (LMICs). Consequently, a steep increase of about 40% in cancer deaths is expected there, mainly because of lack of treatment facilities, especially radiotherapy…
-
Journal Article Full text
Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
Glasdegib is approved for treating acute myeloid leukemia in elderly patients at 100 mg once daily in combination with low‐dose cytarabine. Exposure‐efficacy analysis showed that the survival benefit of glasdegib was not glasdegib exposure‐dependent. The relationship between glasdegib exposure and…
-
Journal Article Full text
VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation
After allogeneic hematopoietic stem cell transplantation (HSCT), recovery of humoral immunity is essential to protect from life-threatening infections. However, monitoring the humoral immune system after transplantation with standard techniques in the clinical routine is imprecise. Here, we…
-
Journal Article Full text
Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication
Some 30% of acute myeloid leukemia (AML) patients display an internal tandem duplication (ITD) mutation in the FMS-like tyrosine kinase 3 (FLT3) gene. FLT3-ITDs are known to drive hematopoietic stem cells towards FLT3 ligand independent growth, but the effects on dendritic cell (DC) differentiation…
-
Journal Article Full text
Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia
Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are one of the most frequent chromosomal aberrations in acute myeloid leukemia. We evaluated the function of Meningioma 1 (MN1), a co-factor of HOXA9 and MEIS1, in human and murine MLL-rearranged leukemia by CRISPR-Cas9 mediated deletion of…
-
Journal Article Full text
Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
Isolated myeloid sarcoma (MS) is a rare malignancy in which myeloid blast forms tumors at various locations while the bone marrow (BM) remains cytomorphologically free from disease. We analyzed isolated MS from four patients and their BMs at initial diagnosis and follow-up, using a custom…